Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1

Digestive Diseases and Sciences

Volumn 59, Issue 1, 2014, Pages 78-88

  Clemons, Nicholas J ^a,b   Do, Hongdo ^a,b   Fennell, Christina ^a   Deb, Siddhartha ^a,b   Fellowes, Andrew ^a   Dobrovic, Alexander ^a,b   Phillips, Wayne A ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Barrett's esophagus; Cell line; Esophageal adenocarcinoma; SMAD4; TP53; Xenograft

Indexed keywords

BETA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICROSATELLITE DNA; PROTEIN P16; PROTEIN P53; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BARRETT ESOPHAGUS; CANCER CELL; CANCER CELL CULTURE; CARCINOGENICITY; CELL ISOLATION; CONTROLLED STUDY; DNA METHYLATION; ESOPHAGEAL ADENOCARCINOMA; FATALITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENOTYPE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROSATELLITE MARKER; MISSENSE MUTATION; MOUSE; NONHUMAN; OANC1 CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SCID MOUSE; TUMOR GENE;

EID: 84893686139     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2882-8     Document Type: Article

References (44)

1. Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol. 2013;23:3-9.
2. Polednak AP. Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas. Int J Cancer. 2003;105:98-100.
3. Crane SJ, Locke GR 3rd, Harmsen WS, Zinsmeister AR, Romero Y, Talley NJ. Survival trends in patients with gastric and esophageal adenocarcinomas: a population-based study. Mayo Clin Proc. 2008;83:1087-1094.
4. Bouvier AM, Binquet C, Gagnaire A, Jouve JL, Faivre J, Bedenne L. Management and prognosis of esophageal cancers: has progress been made? Eur J Cancer. 2006;42:228-233.
5. Younes M, Henson DE, Ertan A, Miller CC. Incidence and survival trends of esophageal carcinoma in the United States: racial and gender differences by histological type. Scand J Gastroenterol. 2002;37:1359-1365.
6. Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer. 2009;101:855-859.
7. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142-146.
8. Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2012;23:3155-3162.
9. Boonstra JJ, Tilanus HW, Dinjens WNM. Translational research on esophageal adenocarcinoma: from cell line to clinic. Dis Esophagus. 2013. doi: 10.1111/dote.12095.
10. Boonstra JJ, van Marion R, Beer DG, et al. Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst. 2010;102:271-274.
11. Dulak AM, Stojanov P, Peng S, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013;45:478-486.
12. Krypuy M, Newnham GM, Thomas DM, Conron M, Dobrovic A. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer. 2006;6:295.
13. Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer. 2008;8:142.
14. Krypuy M, Ahmed AA, Etemadmoghadam D, et al. High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer. 2007;7:168.
15. Do H, Dobrovic A. Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase. Oncotarget. 2012;3:546-558.
16. Wojdacz TK, Dobrovic A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 2007;35:e41.
17. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680-2686.
18. Dangles-Marie V, Pocard M, Richon S, et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res. 2007;67:398-407.
19. Graham TA, McDonald SA. Genetic diversity during the development of Barrett's oesophagus-associated adenocarcinoma: how, when and why? Biochem Soc Trans. 2010;38:374-379.
20. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491:399-405.
21. Fleming NI, Jorissen RN, Mouradov D, et al. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res. 2013;73:725-735.
22. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-1806.
23. Agrawal N, Jiao Y, Bettegowda C, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov. 2012;2:899-905.
24. Phillips WA, Russell SE, Ciavarella ML, et al. Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus. Int J Cancer. 2006;118:2644-2646.
25. Vieth M, Schneider-Stock R, Rohrich K, et al. INK4a-ARF alterations in Barrett's epithelium, intraepithelial neoplasia and Barrett's adenocarcinoma. Virchows Arch. 2004;445:135-141.
26. Sommerer F, Vieth M, Markwarth A, et al. Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. Oncogene. 2004;23:554-558.
27. Lord RV, O'Grady R, Sheehan C, Field AF, Ward RL. K-ras codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction. J Gastroenterol Hepatol. 2000;15:730-736.
28. Kwak EL, Jankowski J, Thayer SP, et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res. 2006;12:4283-4287.
29. Clemons N, Phillips W, Lord RV. Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastresophageal junction. Cancer Biol Ther. 2013. doi: 10.4161/cbt.25362.
30. Barrett MT, Sanchez CA, Galipeau PC, Neshat K, Emond M, Reid BJ. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene. 1996;13:1867-1873.
31. Bian YS, Osterheld MC, Fontolliet C, Bosman FT, Benhattar J. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology. 2002;122:1113-1121.
32. Wong DJ, Barrett MT, Stoger R, Emond MJ, Reid BJ. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res. 1997;57:2619-2622.
33. Hardie LJ, Darnton SJ, Wallis YL, et al. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett. 2005;217:221-230.
34. Sarbia M, Geddert H, Klump B, Kiel S, Iskender E, Gabbert HE. Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract. Int J Cancer. 2004;111:224-228.
35. Dahlberg PS, Jacobson BA, Dahal G, et al. ERBB2 amplifications in esophageal adenocarcinoma. Ann Thorac Surg. 2004;78:1790-1800.
36. Brien TP, Odze RD, Sheehan CE, McKenna BJ, Ross JS. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol. 2000;31:35-39.
37. Rossi E, Villanacci V, Bassotti G, et al. Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization. Diagn Mol Pathol. 2006;15:125-130.
38. Reichelt U, Duesedau P, Tsourlakis M, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol. 2007;20:120-129.
39. Walch A, Specht K, Braselmann H, et al. Coamplification and coexpression of GRB7 and ERBB2 is found in high grade intraepithelial neoplasia and in invasive Barrett's carcinoma. Int J Cancer. 2004;112:747-753.
40. Sehdev V, Peng D, Soutto M, et al. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther. 2012;11:763-774.
41. Zhang K, Zhang S, Jiao X, et al. Slug regulates proliferation and invasiveness of esophageal adenocarcinoma cells in vitro and in vivo. Med Oncol. 2011;28:1089-1100.
42. Santander S, Cebrian C, Esquivias P et al. Cyclooxygenase inhibitors decrease the growth and induce regression. Int J Oncol. 2012;40(2):527-534.
43. Hasina R, Mollberg N, Kawada I, et al. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res. 2013;73:184-194.
44. Alvarez H, Koorstra JB, Hong SM, et al. Establishment and characterization of a bona fide Barrett esophagus-associated adenocarcinoma cell line. Cancer Biol Ther. 2008;7:1753-1755.